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OBJECTIVES This study sought to establish whether the early favorable results in the Benestent-I
randomized trial comparing elective Palmaz-Schatz stent implantation with balloon angio-
plasty in 516 patients with stable angina pectoris are maintained at 5 years.
BACKGROUND The size of the required sample was based on a 40% reduction in clinical events in the stent
group. Seven months and one-year follow-up in this trial showed a decreased incidence of
restenosis and clinical events in patients randomized to stent implantation.
METHODS Data at five years were collected by outpatient visit, via telephone and via the referring
cardiologist. Three patients in the stent group and one in the percutaneous transluminal
coronary angioplasty (PTCA) group were lost to follow-up at five years. Major clinical events,
anginal status and use of cardiac medication were recorded according to the intention to treat
principle.
RESULTS No significant differences were found in anginal status and use of cardiac medication between
the two groups. In the PTCA group, 27.3% of patients underwent target lesion revascular-
ization (TLR) versus 17.2% of patients in the stent group (p 5 0.008). No significant
differences in mortality (5.9% vs. 3.1%), cerebrovascular accident (0.8% vs. 1.2%), myocardial
infarction (9.4% vs. 6.3%) or coronary bypass surgery (11.7% vs. 9.8%) were found between
the stent and PTCA groups, respectively. At five years, the event-free survival rate (59.8% vs.
65.6%; p 5 0.20) between the stent and PTCA groups no longer achieved statistical
significance.
CONCLUSIONS The original 10% absolute difference in TLR in favor of the stent group has remained
unchanged at five years, emphasizing the long-term stability of the stented target site. (J Am
Coll Cardiol 2001;37:1598–603) © 2001 by the American College of Cardiology
This study sought to establish whether the early favorable
results in the Benestent-I randomized trial comparing
elective Palmaz-Schatz stent implantation with balloon
angioplasty in 516 patients with stable angina pectoris are
maintained at five years.
The Benestent-I trial is a randomized study comparing
elective Palmaz-Schatz (Cordis, Warren, New Jersey) stent
implantation (1) with balloon angioplasty in patients with
stable angina pectoris and a single de novo lesion in a native
coronary artery. At seven months, a lower incidence of
restenosis, as well as a lower incidence of major adverse
cardiac events, was found in the stent group (2). A reduced
need for repeat interventions was found at one year (3).
However, stent implantation does not address the underly-
ing disease process. Detrimental mechanisms, such as ac-
celerated atherosclerosis at the stented site, metal corrosion
and endothelial dysfunction have all been proposed as
potential mechanisms of late deterioration but have, so far,
not been documented.
This study sought to answer these questions from the
five-year clinical follow-up status of patients included in the
Benestent-I trial.
METHODS
Study patients. In the Benestent-I trial, patients with
stable angina pectoris and a single de novo lesion ,15 mm
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in length suitable for coronary stent implantation in a native
coronary artery .3 mm in diameter were included.
Eligible patients were randomized to either Palmaz-
Schatz stent implantation or balloon angioplasty. The stent
was deployed at 10 6 8 atm, and the stent artery ratio was
1.12 6 0.15. A total of 516 patients were included—257 in
the balloon group and 259 in the stent group. Clinical and
angiographic characteristics have been previously described
(2,3). The distribution of baseline characteristics was well
balanced in both groups.
Procedure. The procedural technique has been described
in previous reports (2,3). The 15-mm long articulated
Palmaz-Schatz stent (PS 153) was used. Patients undergo-
ing stent implantation received an infusion of Dextran
(1,000 ml over 6 to 8 h) and a 10,000 IU bolus of heparin
at the start of the procedure. An additional heparin bolus
was given each hour during the procedure and continued for
36 h after the procedure. Oral anticoagulation with warfarin
was started after sheath removal and continued for three
months titrated to an international normalized ratio of 2.5
to 3.5.
Patients randomized to balloon angioplasty received a
10,000 IU bolus of heparin at the start of the procedure, and
additional heparin bolus was given during prolonged pro-
cedures. Both treatment groups received a calcium antago-
nist during the hospitalization phase and aspirin 250 to
500 mg daily and dipyridamole, 225 mg daily, for at least six
months.
Five-year clinical follow-up. Clinical information was ob-
tained at the outpatient clinic, by telephone interview or via
the referring physician. A questionnaire, which included
information on occurrence and date of a primary clinical end
point, anginal status according to the Canadian Cardiovas-
cular Society classification (4) and antianginal medication,
was completed.
End points. The primary clinical end points included
death (regardless of cause) cerebrovascular accident (CVA)
(considered hemorrhagic unless demonstrated otherwise),
Q-wave myocardial infarction (MI) (new pathological Q-
wave) (5) or non-Q-wave MI (an increase in serum creatine
kinase levels to more than twice the upper limit of normal
with a concomitant increase in myocardial isoenzyme lev-
els), coronary artery bypass surgery or a second percutaneous
coronary intervention involving the previously treated lesion
for demonstrated myocardial ischemia between the time of
the initial procedure and the follow-up performed at five
years. All events were reviewed by the clinical events
committee. When more than one clinical end point oc-
curred in a patient, only the first event was counted for
survival analysis.
Secondary clinical end points were anginal class and
current medication use (calcium antagonist, beta-adrenergic
blocking agent, nitrate, angiotensin-converting enzyme in-
hibitor and statin).
Statistical analysis. The main clinical analysis consisted of
a single comparison between the two study groups (stent
and balloon) with respect to primary clinical end points,
regardless of the time of occurrence of these events. This
analysis included all patients according to the intention to
treat principle. At the outset of the study, the size of the
required sample (428 patients) was based on an assumed
rate of clinical events of 30% in the angioplasty group and a
reduction of that by 40% in the stent group (by a two-sided
test with an alpha error of 0.05 and a power of 0.80). To
compensate for unsuccessful interventions and losses to
follow-up, the sample was enlarged by 10% (to 470 pa-
tients). In addition, to adjust for a loss of power due to a
planned interim analysis, the sample size was increased by
another 10%, reaching a final size of 520 patients.
Discrete variables are expressed as counts, and percent-
ages and were compared in terms of relative risks (RR) for
stented lesions compared with balloon-dilated lesions, in-
cluding 95% confidence intervals calculated by the method
of Greenland and Robins (6) and Fisher’s exact test.
Event-free survival after stent placement or balloon angio-
plasty was determined by Kaplan-Meier techniques and
displayed as survival curves. Comparison between curves
was performed using the log-rank method.
RESULTS
Follow-up to one year. Results of the Benestent-I trial
have previously been reported (2). There were no differences
in baseline clinical and angiographic characteristics between
the two study groups. Acute angiographic and procedural
success rates were similar in the two groups. There was also
no difference in the incidence of major clinical events
between the groups during the hospital stay. However,
bleeding and vascular complications were more frequently
seen in the stent group (13.5% vs. 3.1%; RR: 4.34; 95%
confidence interval (CI): 2.05 to 9.18; p 5 0.001), who
received full anticoagulation with coumadin.
At seven months, a primary clinical end point was
reached in 29.6% of patients in the percutaneous translu-
minal coronary angioplasty (PTCA) group versus 20.1% of
patients randomized to stent implantation (RR: 0.68, 95%
CI: 0.50 to 0.92; p 5 0.02). Repeat coronary angioplasty
involving the treated segment was more frequent in the
PTCA group (20.6% vs. 10%; RR: 0.49; 95% CI: 0.31 to
0.75; p 5 0.001).
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CI 5 confidence interval
CVA 5 cerebrovascular accident
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
RR 5 relative risk
STRESS 5 Stent Restenosis trial
TLR 5 target lesion revascularization
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At a mean follow-up of 12 months, there was no
significant difference in mortality (0.8% vs. 0.8%), stroke
(0% vs. 0.8%), MI (5.5% vs. 4.7%) or coronary bypass graft
surgery (7.4% vs. 5.9%) between the stent and PTCA
groups. A continued reduced need for repeat angioplasty
procedures was found in the stent group (15.2% vs. 24.2%,
p 5 0. 01). No difference was found between the two groups
with respect to anginal status and prescribed medication.
Five-year follow-up. Information was obtained from 511
patients included in the study who were alive at one-year
follow-up. Three patients in the stent group (1.2%) and one
in the PTCA group (0.4%) were lost to follow-up.
Information was obtained by visits to the outpatient clinic
(77 patients; 15%), by telephone (302 patients; 60%), via the
referring cardiologist (101 patients; 20%) and by other
means (27 patients; 5%). All data were collected five years
after the initial interventional procedure (range: 1,540 to
2,775 days).
Of the 256 patients randomized to stent implantation
(three lost to follow-up), 168 (65.6%) were free of major
adverse cardiac and cerebrovascular events versus 153 of the
256 (59.8%) patients randomized to PTCA (one lost to
follow-up).
The rankings for major events and total counts for events
are presented in Table 1. A primary clinical end point was
reached in 40.2% of 256 patients in the PTCA group versus
34.4% of 256 patients randomized to stent implantation
(RR: 0.85; 95% CI: 0.68 to 1.07; p 5 0.20) (Fig. 1). Thus,
the difference in the overall incidence of end points, which
was significant at one year, did not reach statistical signifi-
cance at five years.
However, the reduced need for repeat PTCA (17.2% vs.
27.3%; RR: 0.63; 95% CI: 0.45 to 0.88; p 5 0.008) was
maintained in the stent group. Between seven months and
five years after the procedure, there were 22 additional cases
of target lesion revascularization (TLR) in the PTCA group
versus 21 in the stent group (total count of events).
The total mortality rate was somewhat higher in the stent
group than it was in the PTCA group (5.9% vs. 3.1%; p 5
0.20). While the difference in cardiac mortality was 2.7%
versus 1.2% (p 5 0.34), the difference in noncardiac
mortality was 3.1% versus 2.0% (p 5 0.58) (Table 2).
The distribution of anginal class was similar in both
groups as was the use of cardiac medications at five years,
except for the use of nitrates, which was significantly lower
in the stent group (p 5 0.002).
DISCUSSION
Summary of findings. Only four patients (0.8%) of the 511
patients included in the original Benestent study who were
alive at one year were lost to follow-up at five years. Due to
a change in the organization at one institution, three
patients from this institution were lost to follow-up at five
years, although they were seen at the outpatient clinic at one
year.
This relatively large study population allows a reliable
comparison in long-term outcome between coronary stent
implantation and PTCA. Questionnaires were used to
document and verify clinical events and symptomatic status.
In this study no significant differences were found in
death, CVA, MI and coronary artery bypass grafting
(CABG) rates after five years. The 10% absolute difference
in TLR rate in favor of stenting versus balloon angioplasty
remained unchanged at five years.
Long-term follow-up of patients treated with Palmaz-
Schatz stents. RANDOMIZED TRIALS. The longest
follow-up of patients randomized to PTCA or Palmaz-
Schatz stent implantation reported so far has been one year
for the Benestent-I study (3) and one year for the Stent
Restenosis (STRESS) trial (7).
After one year, the Benestent-I study showed no signif-
icant differences in mortality, stroke, MI or CABG between
the stent and PTCA groups. However, the need for a repeat
Table 1. Major Adverse Cardiac and Cerebrovascular Events
in Descending Order of Severity and Followed by the Total
Number of Events
Event
Angioplasty
(n 5 256)
Stent
(n 5 256)
Relative Risk
(95% CI)n % n %
Death
1 yr* 2 0.8 2 0.8
5 yrs 8 3.1 15 5.9
All events† 8 3.1 15 5.9 1.88 (0.81–4.34)
CVA
1 yr* 2 0.8 0
5 yrs 3 1.2 1 0.4
All events† 3 1.2 2 0.8 0.67 (0.11–3.96)
Q-wave MI
1 yr* 6 2.3 11 4.3
5 yrs 9 3.5 18 7.0
All events† 10 3.9 20 7.8 2.00 (0.90–4.19)
Non-Q-wave MI
1 yr* 5 2.0 3 1.2
5 yrs 6 2.3 4 1.6
All events† 6 2.3 4 1.6 0.67 (0.19–2.33)
CABG
1 yr* 14 5.5 16 6.3
5 yrs 21 8.2 25 9.8
All events† 25 9.8 30 11.7 1.20 (0.73–1.98)
Repeat PTCA
1 yr* 52 20.3 28 10.9
5 yrs 56 21.9 25 9.8
All events† 70 27.3 44 17.2 0.63 (0.45–0.88)
Any event
1 yr* 81 31.6 60 23.4 0.74 (0.56–0.99)
5 yrs 103 40.2 88 34.4 0.85 (0.68–1.07)
*In the paper of Macaya et al. (3), the one-year results at a mean follow-up were
presented, whereas the one-year data presented in this Table are censored at 400 days.
†“All events” refers to the total count of events at five years (i.e., if a patient
required repeat angioplasty and later coronary artery bypass grafting, “all events” at five
years would reflect both events, not just the first that occurred).
CABG 5 coronary artery bypass grafting; CI 5 confidence interval; CVA 5
cerebrovascular accident; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty.
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angioplasty procedure was significantly lower in the stent
group than it was in the PTCA group (15% vs. 24%, p 5
0.01), and overall primary end points were less frequently
reached by patients in the stent group than they were by
those in the PTCA group (23.4% vs. 31.6%; p 5 0.04).
In the original STRESS I (7), 407 patients with symp-
tomatic ischemic heart disease and new lesions of the native
coronary circulation were randomly assigned to treatment
with either the Palmaz-Schatz coronary stent or PTCA.
Ninety-seven percent of all patients had complete follow-up
beyond eight months, and 94% beyond 11 months. Anginal
status between 9 and 15 months after the procedure was
available for 78% of patients. At one year, 154 patients
(75%) assigned to stent implantation and 141 (70%) as-
signed to PTCA were free of all clinical events (death, MI
or any revascularization procedure), and 162 stent patients
(79%) and 149 PTCA patients (74%) were free from death,
MI or TLR. Symptom-driven TLR occurred in 12% of the
stent group versus 17% of the PTCA group. None of these
differences in clinical events, which favored the stent group,
reached statistical significance. Freedom from angina at one
year was reported with equal frequency in both groups (84%).
Long-term follow-up of patients treated with Palmaz-
Schatz stents. NONRANDOMIZED TRIALS. Klugherz et al.
(8) reported on three-year clinical follow-up after Palmaz-
Schatz stenting in a cohort of 65 consecutive patients who
electively received Palmaz-Schatz intracoronary stents.
At a mean follow-up of 39 6 17 months, absolute
survival and event-free survival at three years were 88% and
56%, respectively. Three-year freedom from stent-site re-
vascularization was 66%. Predictors of decreased long-term
survival included diabetes and a high angina score (Cana-
dian Cardiovascular Society class III/IV) at 6 and 12
months after stenting. Predictors of decreased event-free
survival included a high angina score at 3, 6 and 12 months
after stenting, smaller stent deployment balloon size and a
greater number of stents implanted. Freedom from adverse
events by six months after stenting also correlated with
long-term event-free survival. Eighty-five percent of stent-
site revascularizations occurred within one year. During
Figure 1. Five-year event-free survival of patients enrolled in the Benestent-I trial. Left upper panel: Kaplan-Meier event-free survival curves for death,
cerebrovascular events or myocardial infarction of patients assigned to stenting (dashed line) versus balloon angioplasty (solid line). Right upper panel:
Kaplan-Meier event-free curves for any revascularization (CABG and re-PTCA of the target lesion) of patients assigned to stenting (dashed line) versus
balloon angioplasty (solid line). Left bottom panel: Kaplan-Meier event-free curves for re-PTCA of the target lesion of patients assigned to stenting
(dashed line) versus balloon angioplasty (solid line). Right bottom panel: Kaplan-Meier event-free survival for death, cerebrovascular events, myocardial
infarction or any revascularization of patients assigned to stenting (dashed line) versus balloon angioplasty (solid line). CABG 5 coronary artery bypass
grafting; CVA 5 cerebrovascular accident; FE 5 Fisher’s exact test; LR 5 Log Rank test; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty; RR 5 relative risk.
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follow-up, the majority of adverse events and stent-site
revascularizations occurred early after stenting, and disease
progression in nonstented vessels accounted for the majority
of late revascularization events.
Laham et al. (9) published data on the long-term (four-
to six-year) outcome of Palmaz-Schatz stenting in native
coronary arteries and saphenous vein coronary bypass grafts.
The study cohort consisted of 175 consecutive patients
who underwent elective placement of 194 Palmaz-Schatz
stents in 185 vessels. Clinical events (death, MI, recurrent
angina or any revascularization) were assessed at six weeks,
two, four and six months, one year and yearly thereafter.
Clinical follow-up was available on all patients at a mean of
54 6 17 months. Angiographic success was achieved in 173
patients (98.9%); angiographic restenosis was observed at six
months in 26.1% of target sites. The survival rate was 86.7%
at five years, with a five-year event-free survival rate decreas-
ing progressively to 50.7%, reflecting primarily repeat revas-
cularization procedures (41.2% at five years). However, the
TLR rates were 14.4%, 17.7% and 19.8% at one, three and
five years, respectively, with late (one-year) TLR for in-
stent restenosis in only three patients (1.7%). Rates of both
five-year survival (70.5% vs. 93.4%) and event-free survival
(21.1% vs. 63.3%) were lower for patients who underwent
saphenous vein graft stenting than for those with native
coronary artery stenting. However, five-year TLR rates were
similar for saphenous vein grafts (21.9%) and native vessels
(19.2%), indicating that the higher incidence of repeat
revascularization for saphenous vein grafts was due to an
increase in non-TLR for progressive disease at other sites.
These studies show that the progressive increase in repeat
revascularization over longer periods as well as most ongo-
ing late events can largely be attributed to the progression of
coronary disease at other sites, rather than to late deterio-
ration of the stent result itself. These observations are
concordant with our own observations in this trial.
Conclusions. The high proportion of noncardiac deaths
and Q-wave MIs, potentially unrelated to the stented vessel,
obscures the long-term benefit of stent implantation. Al-
though not statistically significant, a higher percentage of
patients in the stent group developed cancer. A relation
between the development of malignant diseases and stent
implantation seems to be very unlikely, although fluoros-
copy times were probably longer in the stent group. How-
ever, beyond the censored date of 2,000 days, three cases of
malignant disease were found in the PTCA group, thereby
decreasing the apparent difference in the incidence of
malignant disease between the two groups.
Although late migration of the stent, metal fatigue,
endarteritis, late restenosis and accelerated atherosclerosis at
the site of stenting have all been proposed as potential late
clinical complications of coronary stent implantation, none
of these putative complications manifested themselves in the
current study population or in other long-term studies
involving implantation of metallic coronary stents.
The long-term follow-up results of the Benestent-I trial
show that the original difference of 10% in TLR observed at
seven months has remained unchanged at five years, em-
phasizing the extraordinary long-term stability of the dilated
or stented target site. However, the relatively high frequency
of noncardiac deaths and Q wave MIs in the stent group,
potentially unrelated to the deterioration of the target
lesion, result in the difference in freedom from major
cardiovascular and cerebrovascular events no longer achiev-
ing statistical significance at five years (RR: 0.85; CI: 0.68 to
1.07, p 5 0.20).
APPENDIX
PRINCIPAL INVESTIGATORS AND PARTICIPATING
INSTITUTIONS FOR THE BENESTENT-I TRIAL—
FIVE-YEAR FOLLOW-UP
Argentina: Instituto Cardiovascular de Buenos Aires,
Buenos Aires: J. Belardi, MD, R. Henquin, MD.
Belgium: CHR Hoˆpital de la Citadelle, Lie`ge: P. Ma-
terne, MD, J. Boland, MD; Cliniques Universitaires de
Saint-Luc, Brussels: J. Renkin, MD; Onze Lieve Vrouw
Ziekenhuis, Aalst: G.R. Heyndrickx, MD; Academisch
Ziekenhuis Middelheim, Antwerp: P. van den Heuvel,
MD; CHU Sart Tilman, Lie`ge: V. Legrand, MD.
France: Centre Cardiologique du Nord, Saint Denis: B.
Chevalier, MD, B. Glatt, MD, P. Guyon, MD; Clinique
Pasteur, Toulouse: J. Fajadet, MD, J. Marco, MD; Poly-
clinique Volney, Rennes: C. Bourdonnec, MD; CHR
Nancy, Vandoeuvre les Nancy: N. Danchin, MD.
Germany: Christian Albrechts Universita¨t, Kiel: R. Simon,
MD; Universita¨tsklinikum Charite´, Berlin: W. Rutsch, MD.
Ireland: St. James’s Hospital, Dublin: P. Crean, MD.
Italy: Centro Cuore Columbus, Milan: A. Colombo, MD;
Ospedale Maggiore, Trieste: A. Salvi, MD, L. Dreas, MD.
Table 2. Causes of Death
Event
Angioplasty
(n 5 256)
Stent
(n 5 256)
Cardiac 3 (1.2%) 7 (2.7%)
Subacute occlusion 0 1 (within 30 days)*
Arrest 0 1 (acute pulmonary
edema)
Myocardial
Infarction
1† 2†
Sudden death 1 1
Hypovolemic shock 0 1*
Unknown 1 1
Noncardiac 5 (2.0%) 8 (3.1%)
Malignancy 1 (metastatic,
unknown origin)
6 (3 lung, 1 breast,
2 ORL cancer)
Pulmonary embolism 1 1
CVA 1 1
Pulmonary disease 1 0
Suicide in prison 1* —
*These patients have been described in detail in the original publication of
Benestent-I trial (N Engl J Med 1994;331:489–95); †Clinical assessment without
electrocardiogram localization.
CVA 5 cerebrovascular accident; ORL 5 othorinolaryngo carcinoma.
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Spain: Hospital Clinico San Carlos, Madrid: C. Macaya,
MD, L. Lo´pez Ferrero, MD; Hospital Universitario Gre-
gorio Maranon, Madrid: E. Garcia Fernandez, MD.
Sweden: Sahlgrenska Hospital, Go¨teborg: P. Albertsson,
MD.
Switzerland: Faculte´ de Me´de´cine FMH, Geneve: P.
Delafontaine, MD, E. Camenzind, MD; Centre Hospi-
talier Universitaire de Vaudois, Lausanne: J.J. Goy, MD, E.
Eeckhout, MD.
The Netherlands: Catharina Ziekenhuis, Eindhoven:
J.J.R.M. Bonnier, MD; St. Antonius Ziekenhuis, Nieu-
wegein: E.G. Mast, MD; Onze Lieve Vrouwe Gasthuis,
Amsterdam: F. Kiemeneij, MD; AZR Dijkzigt, Rotterdam:
P.W. Serruys, MD, A. Wardeh, MD; Academisch Medisch
Centrum, Amsterdam: K. Koch, MD; Ziekenhuis De
Weezenlanden, Zwolle: H. Suryapranata, MD; Academisch
Ziekenhuis Groningen, Groningen: A. J. van Boven, MD.
United Kingdom: Royal Brompton & National Heart
Hospital, London: U. Sigwart, MD.
Reprint requests and correspondence: Dr. Patrick W. Serruys,
Department of Interventional Cardiology, Thoraxcenter Bd 418,
University Hospital Dijkzigt, Rotterdam, the Netherlands.
E-mail: serruys@card.azr.nl.
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